Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

Blood

Volumn 99, Issue 6, 2002, Pages 1909-1912

  Pedersen Bjergaard, Jens ^a   Andersen, Mette K ^a   Christiansen, Debes H ^a   Nerlov, Claus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; GYRASE INHIBITOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE CLASSIFICATION; DRUG EFFECT; GENE DELETION; HUMAN; MYELODYSPLASIA; PATHOGENESIS; PRIORITY JOURNAL; RADIATION HAZARD; RECURRENT DISEASE; REVIEW;

EID: 0037085745     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.1909     Document Type: Review

References (60)

1. Lessons from hereditary colorectal cancer
2. Therapy-related myelodysplasia and acute myeloid leukemia: Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series
3. International scoring system for evaluating prognosis in myelodysplastic syndromes
4. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MCR AML 10 trial
5. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7
6. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL)
7. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
8. Acute non-lymphocytic leukaemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung
9. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
10. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q
11. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II
12. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia
13. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
14. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
15. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases
16. Possible coexistence of ras activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes
17. Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7 [abstract]
18. Distinct genetic involvement of the TP53 gene in therapyrelated leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype
19. Mutations with loss of heterozygosity of p53 are common in therapy-related MDS and AML following exposure to alkylating agents, and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis
20. Further characterization of complex chromosomal rearrangements in myeloid malignancies: Spectral karyotyping adds precision in defining abnormalities associated with poor prognosis
21. Multi-color FISH in 54 patients with therapy-related MDS/AML
22. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents
23. Epipodo-phyllotoxin-related acute myeloid leukemia: A study of 35 cases
24. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders
25. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
26. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature
27. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: Rare events related to DNA-topoisomerase II inhibitors?
28. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors
29. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis
30. Therapy-related acute promyelocytic leukemia: A report on 16 cases
31. Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II: A report of two cases and a review of the literature
32. Increase therapy-related leukemia secondary to breast cancer
33. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements
34. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nycleoporin NUP98 and class I homeoprotein HOXA9
35. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10
36. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia
37. NUP98 is fused to PMXI homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15)
38. The t(11;20)(p15; q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion
39. Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia
40. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy
41. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia
42. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
43. FLT3 length mutations in AML: Correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients
44. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics
45. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavourable subset of AML
46. Altered myeloid development and acute leukaemia in transgenic mice expressing PML/RARA under control of cathepsin G regulatory sequences
47. A PML/RARa transgene initiates murine acute promyelocytic leukemia
48. Acute leukemia with promyelocytic features in PML/RARα transgenetic mice
49. Distinct leukemia phenotypes in transgenetic mice and diferent corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZRARα and PML-RARα
50. An MLL-AF-fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
51. Immortaization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL
52. Human AML1/MDS1/EV1 fusion protein induces an acute myelogenous leukemia (AML) mice: A model for human AML
53. Expression of a knocked-in AML1-ETO leukemia gene inhibits I he establishment of normal definitive hematopoies is and directly generates dysplastic hematopoietic progenitors
54. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
55. The PEBP2β/MYH11 fusion created by inv(16)(p13; q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia
56. The fusion gene CBFB-MYH11 blocks myeloid differentation and predisposes mice to acute myelomonocytic leukaemia
57. Seed versus soil: The importance of the target cell for transgenic models of human leukemias
58. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation
59. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia
60. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia